ZAP Surgical

ZAP Surgical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

ZAP Surgical is a private medical device company that has developed the ZAP-X, a next-generation, dedicated cranial stereotactic radiosurgery platform. Its key innovations include self-shielding that eliminates the need for costly radiation bunkers, cobalt-free linear accelerator technology, and a unique gyroscopic delivery system designed for superior dosimetry. The company is in the commercial stage, with systems installed in clinical centers globally, and is exploring new clinical applications like radiomodulation for psychiatric conditions.

OncologyNeurologyPsychiatry

Technology Platform

ZAP-X® Gyroscopic Radiosurgery® platform: a self-shielded, cobalt-free, dedicated cranial stereotactic radiosurgery system using a 3 MV linear accelerator and a dual independent gantry for non-coplanar radiation delivery.

Funding History

2
Total raised:$75M
Series B$50M
Series A$25M

Opportunities

The primary opportunity is to capture a significant share of the large, underserved global SRS market by enabling cost-effective, vault-free installations in community hospitals and outpatient centers.
A secondary, high-potential opportunity lies in pioneering the new field of non-ablative radiomodulation for psychiatric and neurological disorders.

Risk Factors

Key risks include commercial execution against entrenched competitors, the need to build a robust long-term clinical evidence base, the high burn rate and financial dependencies of a private medtech company, and the speculative nature of its radiomodulation research program.

Competitive Landscape

ZAP-X competes primarily with Elekta's Gamma Knife (the historical gold standard for dedicated cranial SRS) and with adapted multi-purpose LINACs from Varian (now part of Siemens Healthineers) and Elekta. Its key differentiators are the elimination of radiation vaults and radioactive sources, which targets the economic and logistical barriers of its competitors.